X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (922) 922
Publication (42) 42
Book Review (12) 12
Conference Proceeding (4) 4
Dissertation (4) 4
Book Chapter (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
empagliflozin (897) 897
index medicus (522) 522
diabetes (342) 342
humans (331) 331
type 2 diabetes (323) 323
endocrinology & metabolism (284) 284
dapagliflozin (272) 272
glucose (265) 265
diabetes mellitus, type 2 - drug therapy (250) 250
diabetes mellitus (232) 232
canagliflozin (227) 227
double-blind (215) 215
hypoglycemic agents - therapeutic use (167) 167
sglt2 inhibitor (164) 164
sodium (157) 157
sglt2 inhibitors (153) 153
metformin (149) 149
sodium-glucose transporter 2 - antagonists & inhibitors (149) 149
male (146) 146
cardiac & cardiovascular systems (145) 145
safety (145) 145
dextrose (142) 142
heart failure (140) 140
pharmacology & pharmacy (138) 138
type 2 diabetes mellitus (133) 133
glucosides - therapeutic use (130) 130
benzhydryl compounds - therapeutic use (125) 125
female (124) 124
clinical trials (117) 117
mortality (117) 117
middle aged (115) 115
blood pressure (111) 111
risk (110) 110
efficacy (107) 107
analysis (104) 104
risk factors (104) 104
mellitus (101) 101
glycemic control (99) 99
type-2 diabetes-mellitus (99) 99
cardiovascular diseases (98) 98
insulin (97) 97
outcomes (94) 94
treatment outcome (94) 94
aged (91) 91
hypoglycemic agents - adverse effects (90) 90
cardiovascular disease (88) 88
care and treatment (88) 88
disease (87) 87
add-on (86) 86
internal medicine (86) 86
blood-pressure (85) 85
hypoglycemic agents (85) 85
cardiovascular outcomes (84) 84
medicine, general & internal (84) 84
adult (80) 80
heart-failure (80) 80
inhibitors (80) 80
medicine & public health (78) 78
animals (77) 77
diabetes mellitus, type 2 - complications (76) 76
diabetes mellitus, type 2 - blood (73) 73
patients (73) 73
body weight (71) 71
drug therapy (71) 71
hyperglycemia (71) 71
glucosides - adverse effects (70) 70
benzhydryl compounds - adverse effects (67) 67
sodium-glucose transporter 2 - metabolism (65) 65
diabetes therapy (62) 62
kidney diseases (62) 62
review (62) 62
liraglutide (61) 61
cardiology (60) 60
heart diseases (59) 59
hypertension (59) 59
blood glucose - drug effects (58) 58
abridged index medicus (54) 54
add-on therapy (54) 54
hypoglycemia (54) 54
glucose transporter (53) 53
hypoglycemic agents - pharmacology (53) 53
kidney-disease (53) 53
hypoglycemic agents - administration & dosage (52) 52
inadequate glycemic control (52) 52
peripheral vascular disease (51) 51
type-2 (51) 51
benzhydryl compounds - pharmacology (50) 50
blood glucose - metabolism (50) 50
glucosides - pharmacology (50) 50
glucosides - administration & dosage (49) 49
kidneys (49) 49
double-blind method (48) 48
pharmacokinetics (47) 47
glycosylated hemoglobin (46) 46
medical research (46) 46
meta-analysis (46) 46
sglt2 (46) 46
benzhydryl compounds - administration & dosage (45) 45
cotransporter 2 inhibitors (45) 45
endocrinology (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (872) 872
German (22) 22
Spanish (10) 10
Czech (9) 9
French (7) 7
Japanese (7) 7
Russian (5) 5
Korean (2) 2
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


DIABETES CARE, ISSN 0149-5992, 05/2014, Volume 37, Issue 5, pp. 1480 - 1483
OBJECTIVEAdjunctive-to-insulin therapy with sodium-glucose cotransporter 2 (SGLT2) inhibition may improve glycemic control in type 1 diabetes (T1D).RESEARCH... 
INSULIN | ENDOCRINOLOGY & METABOLISM | KETOACIDOSIS | EMPAGLIFLOZIN | SGLT-2 INHIBITOR
Journal Article
NATURE REVIEWS NEPHROLOGY, ISSN 1759-5061, 12/2017, Volume 13, Issue 12, pp. 728 - 729
New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2... 
UROLOGY & NEPHROLOGY | OUTCOMES | LIRAGLUTIDE | KIDNEY | EMPAGLIFLOZIN
Journal Article
AMERICAN JOURNAL OF MEDICINE, ISSN 0002-9343, 06/2017, Volume 130, Issue 6, pp. S1 - S3
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 12/2019, Volume 170, p. 113677
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial made evident the potentiality... 
Heart | Ceramides | Empagliflozin | Metabolomics | Sphingolipids | Glycerophospholipids
Journal Article
NATURE REVIEWS NEPHROLOGY, ISSN 1759-5061, 02/2018, Volume 14, Issue 2, pp. 78 - 78
2017 saw the emergence of a new era in renoprotective medicine for diabetic kidney disease with reports of promising renal outcomes with the sodium-glucose... 
UROLOGY & NEPHROLOGY | OUTCOMES | TYPE-2 | EMPAGLIFLOZIN
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 02/2020, Volume 501, p. 110642
The beneficial effects of empagliflozin (EMPA) on cardiac functions during ischemia and reperfusion were characterized. The contractile functions of isolated... 
Empagliflozin | AMPK | Ischemia/reperfusion injury | Non-diabetic mice
Journal Article
Circulation, ISSN 0009-7322, 08/2016, Volume 134, Issue 8, pp. 571 - 573
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 07/2019, Volume 21, Issue 7, pp. 874 - 876
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 08/2019, Volume 7, Issue 8, pp. 606 - 617
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic... 
MORTALITY | URINARY ALBUMIN | CARDIOVASCULAR EVENTS | RISK | INHIBITORS | OUTCOMES | EQUATION | EMPAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM
Journal Article
European Heart Journal, ISSN 0195-668X, 06/2018, Volume 39, Issue 24, pp. 2221 - 2225
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 01/2019, Volume 7, Issue 1, pp. 4 - 5
Journal Article
Respiratory Physiology & Neurobiology, ISSN 1569-9048, 02/2020, Volume 273, p. 103316
Lung fibrosis is one of the serious complications of bleomycin use in cancer therapy. The aim of this study was to investigate the effect of pre-treatment... 
Empagliflozin | Mice | Pulmonary fibrosis | Bleomycin | Treatment
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 12/2019, Volume 498, p. 110539
To evaluate the pleiotropic effects of empagliflozin in the liver through lipogenesis, beta-oxidation, and endoplasmic reticulum stress pathways. Male C57Bl/6... 
Empagliflozin | Hepatic steatosis | Lipogenesis | Endoplasmic reticulum stress | INDUCED HEPATIC STEATOSIS | OXIDATIVE STRESS | TRANSCRIPTION | NONALCOHOLIC STEATOHEPATITIS | ENDOPLASMIC-RETICULUM STRESS | COTRANSPORTER 2 INHIBITION | LIVER-DISEASE | CELL BIOLOGY | DIET | SGLT2 INHIBITOR EMPAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | TYPE-2 DIABETES-MELLITUS
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2018, Volume 72, Issue 15, pp. 1845 - 1855
Patients with type 2 diabetes mellitus have an increased risk for the development of cardiac and other vascular events, heart failure (HF), and decline in... 
heart failure | renal function | diabetes | SGLT2 inhibitor | KIDNEY-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | DAPAGLIFLOZIN | SGLT2 INHIBITORS | HEART-FAILURE | RISK | DEATH | ESTABLISHED CARDIOVASCULAR-DISEASE | PHARMACOKINETICS | OUTCOMES | EMPAGLIFLOZIN
Journal Article
AMERICAN JOURNAL OF CARDIOLOGY, ISSN 0002-9149, 07/2017, Volume 120, Issue 1, pp. S1 - S3
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.